- Greater Cannabis ( OTCQB:GCAN ) said on Friday it had submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its neuropsychiatric cannabinoid therapy.
- ( OTCQB:GCAN ) has risen 25% .
- The Company intends to conduct a Phase 2 clinical trial to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses.
- The study will have 100 patients ranging in age from 4-17 years old.
- The study is expected to begin enrolling patients in the first half of 2023.
For further details see:
Greater Cannabis rises 25% on submitting phase 2 trial application to treat autism in Israel